

Autism Spectrum Disorder/Intellectual Disability Panel Analysis

- I. The use of an [autism spectrum disorder](#) / [intellectual disability](#) panel is considered **investigational** for all indications.

DEFINITIONS

1. **Autism spectrum disorder** is defined in the DSM V as persistent deficits in social communication and social interaction across multiple contexts, as manifested by the following, currently or by history:
 - a. Deficits in social-emotional reciprocity, ranging, for example, from abnormal social approach and failure of normal back-and-forth conversation; to reduced sharing of interests, emotions, or affect; to failure to initiate or respond to social interactions.
 - b. Deficits in nonverbal communicative behaviors used for social interaction, ranging, for example, from poorly integrated verbal and nonverbal communication; to abnormalities in eye contact and body language or deficits in understanding and use of gestures; to a total lack of facial expressions and nonverbal communication.
 - c. Deficits in developing, maintaining, and understanding relationships, ranging, for example, from difficulties adjusting behavior to suit various social contexts; to difficulties in sharing imaginative play or in making friends; to absence of interest in peers.

RATIONALE AND REFERENCES

Autism Spectrum Disorder/Intellectual Disability Panel Analysis

Concert Evidence Review for Coverage Determination (Published 06/01/2025)

This review focused on a search for evidence-based guidelines and peer-reviewed, published evidence of the clinical validity and utility of autism spectrum disorder/intellectual disability multigene panel tests. The review was limited to literature published between 05/21/2024 to 05/21/2025. A total of 112 abstracts were identified and 7 full text publications were fully reviewed, none of which met the inclusion criteria.

There were no new guidelines identified and no peer-reviewed literature identified to include in the evidence review.

There is INSUFFICIENT EVIDENCE in published guidelines and peer-reviewed literature to definitively demonstrate improved health outcomes from the use of autism spectrum disorder/intellectual disability multigene panel tests, as compared to the current standard of care. At this time, the available evidence does not support health plan coverage of these tests compared to other, guideline-supported testing methodologies.

Concert Evidence Review for Coverage Determination for Autism Spectrum Disorder/Intellectual Disability Panels. Published 06/01/2025.